These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 33477154)

  • 1. Prolactin Response to Metformin in Cabergoline-Resistant Prolactinomas: A Pilot Study.
    Portari LHC; Correa-Silva SR; Abucham J
    Neuroendocrinology; 2022; 112(1):68-73. PubMed ID: 33477154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Women with prolactinomas presented at the postmenopausal period.
    Shimon I; Bronstein MD; Shapiro J; Tsvetov G; Benbassat C; Barkan A
    Endocrine; 2014 Dec; 47(3):889-94. PubMed ID: 24711223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas.
    Huang HY; Zhai W; Tang H; Hui GZ; Wu ZB
    Endocrine; 2018 Nov; 62(2):464-469. PubMed ID: 30238326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas.
    Iyer P; Molitch ME
    Endocr Pract; 2011; 17(3):e55-8. PubMed ID: 21324816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients.
    Ono M; Miki N; Kawamata T; Makino R; Amano K; Seki T; Kubo O; Hori T; Takano K
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4721-7. PubMed ID: 18812485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different Cabergoline Effect on Metabolic and Anthropometric Parameters in Female Prolactinoma Patients Versus Idiopathic Hyperprolactinemia Patients.
    Aboelnaga MM; Eladawy EH; Elshafei MM; Abdullah N; Shaer ME
    Endocr Metab Immune Disord Drug Targets; 2019; 19(4):511-518. PubMed ID: 30806330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study.
    Krysiak R; Okrzesik J; Okopien B
    Endocrine; 2015 May; 49(1):242-9. PubMed ID: 25239203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis.
    Hu J; Zheng X; Zhang W; Yang H
    Pituitary; 2015 Oct; 18(5):745-51. PubMed ID: 25500765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas.
    Indirli R; Ferrante E; Sala E; Giavoli C; Mantovani G; Arosio M
    Horm Cancer; 2019 Jun; 10(2-3):120-127. PubMed ID: 31001736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of short-term maintenance treatment with cabergoline in microadenoma-related and idiopathic hyperprolactinemia.
    Buyukbayrak EE; Karageyim Karsidag AY; Kars B; Balcik O; Pirimoglu M; Unal O; Turan C
    Arch Gynecol Obstet; 2010 Nov; 282(5):561-6. PubMed ID: 20571820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
    Sabuncu T; Arikan E; Tasan E; Hatemi H
    Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperprolactinemia in children and adolescents and longterm follow-up results of prolactinoma cases: a single-centre experience.
    Kontbay T; Şıklar Z; Özsu E; Uyanık R; Bilici E; Ceran A; Berberoğlu M
    Turk J Pediatr; 2022; 64(5):892-899. PubMed ID: 36305439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mean platelet volume in patients with prolactinoma.
    Tam AA; Kaya C; Başer H; Ersoy R; Çakır B
    Arch Endocrinol Metab; 2016 Aug; 60(4):319-22. PubMed ID: 26886093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Giant cabergoline-resistant prolactinoma in a man who presented with a psychotic episode during treatment: a case report.
    Casulari LA; de Castro LF; Kessler IM; Mendonça JL; de Fátima Magalhães Gonzaga M
    J Med Case Rep; 2019 Jun; 13(1):183. PubMed ID: 31202268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperprolactinemia and prolactinoma.
    Romijn JA
    Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Start low, go slowly - mental abnormalities in young prolactinoma patients under cabergoline therapy.
    Brichta CM; Wurm M; Krebs A; Schwab KO; van der Werf-Grohmann N
    J Pediatr Endocrinol Metab; 2019 Sep; 32(9):969-977. PubMed ID: 31323004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement in cognitive abilities following cabergoline treatment in patients with a prolactin-secreting pituitary adenoma.
    Montalvo I; Llorens M; Caparrós L; Pamias M; Torralbas J; Giménez-Palop O; Caixàs A; Palao DJ; Labad J
    Int Clin Psychopharmacol; 2018 Mar; 33(2):98-102. PubMed ID: 29035904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Speed of response to dopaminergic agents in prolactinomas.
    Hage C; Salvatori R
    Endocrine; 2022 Mar; 75(3):883-888. PubMed ID: 34846682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PRL-R Variants Are Not Only Associated With Prolactinomas But Also With Dopamine Agonist Resistance.
    de Castro Moreira AR; Trarbach E; Bueno CBF; Monteiro ALS; Grande IPP; Padula M; Maciel GAR; Glezer A
    J Clin Endocrinol Metab; 2023 Jun; 108(7):e450-e457. PubMed ID: 36638053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.